News

The exclusivity afforded patent, listed in the Orange Book for Imitrex (sumatriptan succinate) injection, expires on February 6, 2009. Spectrum’s abbreviated new drug application (ANDA) for sumatriptan succinate

This three-year study is the longest study of psoriasis patients receiving continuous treatment with a biologic agent. The trial, a 36-month, phase IIIb open-label study, evaluated the long-term

The study, which assessed Humira (adalimumab) in patients with moderate to severe chronic plaque psoriasis, showed that nearly 70% of patients receiving Humira 40mg every other week experienced

In the study, 54% of patients who received Amevive (alefacept) for 12 weeks achieved an ACR 20 response (a standard measure of disease improvement), or at least a

Schering-Plough and NeoGenesis have had a research collaboration since 1999 and announced that they had entered into the acquisition agreement on January 20. “This acquisition will further strengthen

Under the terms of the agreement, privately-held Chicago Labs will receive an upfront fee of $100,000, and is eligible to receive payments upon achievement of certain development, regulatory

The novel pyrimidine compounds have been shown to control the progress of cells through the cancer cell cycle. One group of the compounds works by inhibiting Cyclin Dependent

If, as expected, the European Commission accepts the recommendation of its Committee for Medicinal Products for Human Use (CHMP), it would be the second major approval of duloxetine

Data from all patients in the study showed a median response duration of more than 45 weeks. Furthermore, analysis of the time to response showed that 85% of